Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
May 2021
-
Featured NewsWorld Asthma Day 2021
Understanding asthma: What are your misconceptions? This World Asthma Day find out more about asthma and challenge your misconceptions.
-
Fighting MS through innovation
Investing in innovative treatments is vital to alleviate the suffering caused by multiple sclerosis (MS).
-
Media ReleaseSandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicineSandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study1Neovascular age-related macular degeneration accounts…
-
From melanoma survivor to front-line nurse
Jordan, a melanoma survivor, shares her experience with melanoma, BRAF mutation testing and the importance of patient empowerment.
-
Media ReleaseNovartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus afliberceptIn KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in diabetic…
April 2021
-
Featured NewsNovartis Financial Results – Q1 2021
Novartis announced the company’s financial results for the first quarter of 2021.
-
Key ReleaseNovartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.Q1 net sales declined -2% (cc¹, +1% USD), due to prior year COVID-19 related forward purchasing (approximately USD 0.4 billion) Pharmaceuticals BU in line with prior year (0% cc, +4% USD) with…
-
Key ReleaseNovartis: moteurs clés de la croissance et lancements poursuivent leur essor au 1er trimestre, maintenant la confiance dans la croissance. Confirmation des prévisions pour le Groupe pour 2021Chiffre d’affaires net du T1 en recul de -2% (tcc¹, +1% USD), impacté par les achats anticipés au T1 2020 en lien avec le Covid-19 (env. USD 0,4 milliard) Pharmaceuticals: le chiffre d’affaires…
-
Key ReleaseWichtige Wachstumstreiber und Neueinführungen von Novartis setzen ihre Dynamik im ersten Quartal fort und erhalten das Vertrauen in das Wachstum; Konzernprognose für 2021 bestätigtDer Nettoumsatz sank im ersten Quartal um –2% (kWk¹, +1% USD) infolge der COVID-19-bedingten Vorratskäufe im Vorjahr (rund USD 0,4 Milliarden) Die Geschäftseinheit Pharmaceuticals blieb…
-
Featured NewsWorld Malaria Day 2021
This year, World Malaria Day is running with the backdrop of countries around the world continuing to fight the COVID-19 pandemic.
-
Media ReleaseNovartis to initiate SMART Phase 3b global study of Zolgensma in children up to 21 kg, building on real-world experienceSMART study to extend data beyond patient population studied in clinical trials New clinical study to evaluate safety and efficacy of Zolgensma in children up to 21 kg, adding to real-world…
-
Media ReleaseKesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMSKesimpta reduced the risk of disability progression independent of relapse activity (PIRA) by up to almost 60% vs first-line teriflunomide in a subgroup of newly diagnosed, treatment-naïve patients…
Pagination
- ‹ Previous page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- …
- 151
- › Next page